[1]汤学超,白 元,张志钢,等.左心耳封堵器临床研究进展[J].介入放射学杂志,2017,(03):281-284.
 TANG Xuechao,BAI Yuan,ZHANG Zhigang,et al.Progress in clinical research of left atrial appendage occluder[J].journal interventional radiology,2017,(03):281-284.
点击复制

左心耳封堵器临床研究进展 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2017年03期
页码:
281-284
栏目:
综述
出版日期:
2017-03-25

文章信息/Info

Title:
Progress in clinical research of left atrial appendage occluder
作者:
汤学超 白 元 张志钢 秦永文
Author(s):
TANG Xuechao BAI Yuan ZHANG Zhigang QIN Yongwen
Department of Cardiology, Affiliated Changhai Hospital, Second Military Medical University, Shanghai 200433, China
关键词:
【关键词】 经皮左心耳封堵术 左心耳封堵器 心房纤维性颤动 脑卒中 预防
文献标志码:
A
摘要:
【摘要】 心房颤动是常见心律失常,是老年人缺血性脑卒中的主要原因之一。左心耳是非瓣膜性房颤(NVAF)形成血栓的主要部位。研究表明封堵左心耳可有效地减少NVAF患者缺血性脑卒中发作,其疗效不亚于华法林预防治疗作用。理想的左心耳封堵器是完成左心耳封堵的关键因素。经过数十年研究,目前临床上常用的左心耳封堵器有Watchman封堵器、ACP封堵器,还有部分封堵器处于临床前试验研究阶段。该文就目前左心耳封堵器研究和临床应用现状作一简要综述。

参考文献/References:

[1] Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation(ATRIA) Study[J]. JAMA, 2001, 285: 2370- 2375.
[2] Saw J. Percutaneous left atrial appendage closure for stroke prevention[J]. Trends Cardiovasc Med, 2016, 26: 200- 201.
[3] 李长永, 张志钢, 白 元, 等. 经皮左心耳封堵装置研究进展[J]. 介入放射学杂志, 2015, 24: 830- 834.
[4] Ostermayer SH, Reisman M, Kramer PH, et al. Percutaneous left atrial appendage transcatheter occlusion(PLAATO system) to prevent stroke in high- risk patients with non- rheumatic atrial fibrillation: results from the international multi- center feasibility trials[J]. J Am Coll Cardiol, 2005, 46: 9- 14.
[5] Bayard YL, Omran H, Neuzil P, et al. PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non- anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study[J]. EuroIntervention, 2010, 6: 220- 226.
[6] Iskandar S, Vacek J, Lavu M, et al. Left atrial appendage closure for stroke prevention devices, techniques, and efficacy[J]. Cardiol Clin, 2016, 34: 329- 351.
[7] Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non- inferiority trial[J]. Lancet, 2009, 374: 534- 542.
[8] Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3- year follow- up of the PROTECT AF(Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial[J]. Circulation, 2013, 127: 720- 729.
[9] Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial[J]. JAMA, 2014, 312: 1988- 1998.
[10] Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long- term warfarin therapy: the PREVAIL trial[J]. J Am Coll Cardiol, 2014, 64: 1- 12.
[11] Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF(PROTECT AF)clinical trial and the Continued Access Registry[J]. Circulation, 2011, 123: 417- 424.
[12] Reddy VY, Mobius- Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology)[J]. J Am Coll Cardiol, 2013, 61: 2551- 2556.
[13] Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the Watchman device: peri- procedural outcomes from the EWOLUTION registry[J]. Eur Heart J, 2016, 37: 2465- 2474.
[14] Lin AC, Knight BP. Left atrial appendage closure[J]. Prog Cardiovasc Dis, 2015, 58: 195- 201.
[15] Plicht B, Konorza TF, Kahlert P, et al. Risk factors for thrombus formation on the Amplatzer Cardiac Plug after left atrial appendage occlusion[J]. JACC Cardiovasc Interv, 2013, 6: 606- 613.
[16] Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug[J]. EuroInter- vention, 2016, 11: 1170- 1179.
[17] Lam YY. A new left atrial appendage occluder (Lifetech LAmbre Device) for stroke prevention in atrial fibrillation[J]. Cardiovasc Revasc Med, 2013, 14: 134- 136.
[18] Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter- based left atrial appendage occlusion[J]. Europace, 2014, 16: 1397- 1416.
[19] Kavinsky CJ, Kusumoto FM, Bavry AA, et al. SCAI/ACC/HRS institutional and operator requirements for left atrial appendage occlusion[J]. J Am Coll Cardiol, 2016, 67: 2295- 2305.
[20] Mobius- Winkler S, Majunke N, Sandri M, et al. Percutaneous left atrial appendage closure: technical aspects and prevention of periprocedural complications with the watchman device[J]. World J Cardiol, 2015, 7: 65- 75.
[21] Meerkin D, Butnaru A, Dratva D, et al. Early safety of the Amplatzer Cardiac PlugTM for left atrial appendage occlusion[J]. Int J Cardiol, 2013, 168: 3920- 3925.

备注/Memo

备注/Memo:
(收稿日期:2016-06-17)
(本文编辑:边 佶)
更新日期/Last Update: 2017-03-14